ASXL1 and acute myeloid leukemia: The strongest differences were observed for SRSF2: 32%, 31%, and 11%; ASXL1: 35%, 34%, and 13%; and STAG2: 16%, 19%, and 2%, in AML, NOS, AML-MRC-MLD, and AML-MRC-C, respectively (Fig. 1C).